{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:18Z","timestamp":1793734218416,"version":"4.6.1"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of retinal and choroidal neovascularization, as well as macular edema (ME), in retinal disorders such as diabetic retinopathy, retinal vein occlusion (RVO), and age-related macular degeneration (ARMD). The advent of intravitreal anti-VEGF therapy has revolutionized their management. More recently, these agents have been explored in several other retinal pathologies characterized by secondary neovascularization, either in vascular or non-vascular disorders. This review summarizes current evidence on the role of anti-VEGF agents in retinal disorders other than ARMD, including central serous chorioretinopathy (CSCR), macular telangiectasia type 2 (MacTel), choroidal osteoma, retinopathy of prematurity (ROP), tubercular granuloma, inherited retinal dystrophies, Coats\u2019 disease, angioid streaks, and retinal vasoproliferative tumors (RVPTs).<\/jats:p>","DOI":"10.4103\/ijo.ijo_3035_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:10Z","timestamp":1777478470000},"page":"661-668","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases"],"prefix":"10.4103","volume":"74","author":[{"given":"Shalini","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr. Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvashi","family":"Kala","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr. Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Bamel","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr. Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr. Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R2-20261103","first-page":"145","article-title":"Anti-VEGF for ROP and pediatric retinal diseases","volume":"7","author":"Wu","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.survophthal.2012.11.007","article-title":"Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2)","volume":"58","author":"Wu","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40942-022-00378-0","article-title":"Spectral domain OCT features in type 2 macular telangiectasia (type 2 MacTel): Its relevance with clinical staging and visual acuity","volume":"8","author":"Venkatesh","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R5-20261103","first-page":"123","article-title":"Anti-vascular endothelial growth factor treatment outcomes in macular telangiectasia: A systematic review","volume":"248","author":"Sriranganathan","year":"2025","journal-title":"Ophthalmologica"},{"key":"R6-20261103","first-page":"1","article-title":"Efficacy and safety of anti vascular endothelial growth factor (Anti-VEGF) in treating neovascular age-related macular degeneration (AMD): A systematic review and meta-analysis","volume":"2022","author":"Yin","year":"2022","journal-title":"J Immunol Res"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archopht.124.4.450","article-title":"Idiopathic macular telangiectasia","volume":"124","author":"Yannuzzi","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2021.75608","article-title":"Clinical features of untreated type 2 macular telangiectasia and efficacy of anti-vascular endothelial growth factor therapy in macular neovascularization","volume":"52","author":"\u00c7oban Karata\u015f","year":"2022","journal-title":"Turk J Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00417-019-04520-x","article-title":"Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia","volume":"258","author":"Karasu","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2010.11.019","article-title":"Monthly ranibizumab for nonproliferative macular telangiectasia type 2: A 12-month prospective study","volume":"151","author":"Charbel Issa","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4274\/tjo.23921","article-title":"Intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia","volume":"46","author":"Aydo\u011fan","year":"2016","journal-title":"Turk J Ophthalmol"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/IAE.0000000000000715","article-title":"Poor long-term outcome of anti- vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2","volume":"35","author":"Kupitz","year":"2015","journal-title":"Retina"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2147\/OPTH.S373538","article-title":"Macular telangiectasia type 2: A comprehensive review","volume":"16","author":"Kedarisetti","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0301-4738.60081","article-title":"Coats\u2019 disease: An Indian perspective","volume":"58","author":"Rishi","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"R15-20261103","first-page":"e225","article-title":"Vascular endothelial growth factor in Coats\u2019 disease","volume":"92","author":"Zhao","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336906","article-title":"Diagnosis and treatment of coats\u2019 disease: A review of the literature","volume":"227","author":"Ghorbanian","year":"2012","journal-title":"Ophthalmologica"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00417-010-1366-1","article-title":"Elevated vascular endothelial growth factor level in Coats\u2019 disease and possible therapeutic role of bevacizumab","volume":"248","author":"He","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1167\/iovs.12-10613","article-title":"Expression of vascular endothelial growth factor in eyes with Coats\u2019 disease","volume":"54","author":"Kase","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12886-017-0469-4","article-title":"The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat\u2019s disease","volume":"17","author":"Li","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"R20-20261103","first-page":"668","article-title":"Treatment of Coats\u2019 disease: An analysis of pooled results","volume":"12","author":"Adeniran","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.survophthal.2013.03.007","article-title":"Current management of Coats disease","volume":"59","author":"Sigler","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10792-019-01095-8","article-title":"Recent advances in the diagnosis and treatment of Coats\u2019 disease","volume":"39","author":"Yang","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjophthalmol-2011-300141","article-title":"Bevacizumab for Coats\u2019 disease with exudative retinal detachment and risk of vitreoretinal traction","volume":"96","author":"Ramasubramanian","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0161-6420(02)01177-6","article-title":"Treatment of retinal capillary hemangioma","volume":"109","author":"Singh","year":"2002","journal-title":"Ophthalmology"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/ICU.0b013e3282fb7c04","article-title":"Ocular von Hippel-Lindau disease: Clinical update and emerging treatments","volume":"19","author":"Wong","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.eye.6702896","article-title":"Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy","volume":"21","author":"Ziemssen","year":"2007","journal-title":"Eye (Lond)"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1111\/j.1755-3768.2009.01594.x","article-title":"Intravitreal bevacizumab for retinal capillary haemangioma: Longterm results","volume":"88","author":"Ach","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1755-3768.2008.01449.x","article-title":"Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma","volume":"88","author":"Mennel","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.4103\/ijo.IJO_1799_18","article-title":"Laser photocoagulation, intravitreal anti-VEGF, and vitreous surgery for the treatment of juxtapapillary retinal capillary hemangioma","volume":"67","author":"Ucan Gunduz","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcjo.2014.07.007","article-title":"Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review","volume":"49","author":"Slim","year":"2014","journal-title":"Can J Ophthalmol"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/eye.2014.113","article-title":"Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours","volume":"28","author":"Rogers","year":"2014","journal-title":"Eye (Lond)"},{"key":"R32-20261103","doi-asserted-by":"crossref","first-page":"32834","DOI":"10.1001\/2013.jamaophthalmol.524","article-title":"Retinal vasoproliferative tumors: Comparative clinical features of primary vs. secondary tumors in 334 cases","volume":"131","author":"Shields","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1755-3768.2008.01331.x","article-title":"Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema","volume":"88","author":"Saito","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.eye.6702782","article-title":"Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin)","volume":"21","author":"Kenawy","year":"2007","journal-title":"Eye (Lond)"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/tjo.tjo_21_22","article-title":"Retinal vasoproliferative tumor regression after intravitreal aflibercept","volume":"13","author":"Chu","year":"2023","journal-title":"Taiwan J Ophthalmol"},{"issue":"Suppl 1","key":"R36-20261103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R38-20261103","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/S0021-9258(17)41787-X","article-title":"Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin","volume":"269","author":"Goldberg","year":"1994","journal-title":"J Biol Chem"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"R44-20261103","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R46-20261103","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.4103\/IJO.IJO_169_23","article-title":"Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy","volume":"71","author":"Sandeep","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R48-20261103","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/OPTH.S174573","article-title":"Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy","volume":"12","author":"Mohabati","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R49-20261103","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","article-title":"Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells","volume":"91","author":"Peters","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R50-20261103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3341\/kjo.2010.24.3.155","article-title":"The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy","volume":"24","author":"Lim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R51-20261103","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000345495","article-title":"Intravitreal ranibizumab for acute central serous chorioretinopathy","volume":"229","author":"Kim","year":"2013","journal-title":"Ophthalmologica"},{"key":"R52-20261103","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00417-010-1581-9","article-title":"The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy","volume":"249","author":"Lim","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R53-20261103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/02713680903428306","article-title":"Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: A prospective, controlled clinical study","volume":"35","author":"Artunay","year":"2010","journal-title":"Curr Eye Res"},{"key":"R54-20261103","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/IAE.0000000000000655","article-title":"Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents","volume":"35","author":"Chhablani","year":"2015","journal-title":"Retina"},{"key":"R55-20261103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","article-title":"A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: The CONTAIN study","volume":"99","author":"Pitcher","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R56-20261103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000314709","article-title":"Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy","volume":"225","author":"Inoue","year":"2010","journal-title":"Ophthalmologica"},{"key":"R57-20261103","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/112067210901900415","article-title":"Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy","volume":"19","author":"Schaal","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R58-20261103","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/eye.2013.236","article-title":"Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: Meta-analysis and review","volume":"27","author":"Chung","year":"2013","journal-title":"Eye (Lond)"},{"key":"R59-20261103","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11096-017-0460-4","article-title":"Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: A meta-analysis","volume":"39","author":"Ji","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"R60-20261103","doi-asserted-by":"crossref","first-page":"210458","DOI":"10.1155\/2014\/210458","article-title":"Role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma","volume":"2014","author":"Mansour","year":"2014","journal-title":"J Ophthalmol"},{"key":"R61-20261103","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00417-007-0636-z","article-title":"Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin)","volume":"245","author":"Ahmadiehand","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R62-20261103","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/IAE.0000000000000187","article-title":"Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma","volume":"34","author":"Khan","year":"2014","journal-title":"Retina"},{"key":"R63-20261103","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4103\/2008-322X.176905","article-title":"Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization","volume":"10","author":"Najafabadi","year":"2015","journal-title":"J Ophthalmic Vis Res"},{"key":"R64-20261103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.15713\/ins.clever.36","article-title":"Non-neovascular subretinal fluid secondary to choroidal osteoma controlled with intravitreal aflibercept \u2013 A case report","volume":"2","author":"Brody","year":"2019","journal-title":"Clin Exp Vis Eye Res"},{"key":"R65-20261103","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/kjo.kjo_79_17","article-title":"Antivascular endothelial growth factor in treatment of choroidal osteoma not associated with choroidal neovascular membrane","volume":"29","author":"Cherian","year":"2017","journal-title":"Kerala J Ophthalmol"},{"key":"R66-20261103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000320013","article-title":"Antivascular endothelial growth factor in hereditary dystrophies","volume":"46","author":"Battaglia Parodi","year":"2010","journal-title":"Dev Ophthalmol"},{"key":"R67-20261103","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1089\/jop.2011.0206","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy","volume":"29","author":"Kapoor","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R68-20261103","first-page":"229","article-title":"Long-term outcome of bevacizumab therapy in sorsby fundus dystrophy, a case series","volume":"58","author":"Kaye","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R69-20261103","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ICB.0000000000000103","article-title":"Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy","volume":"9","author":"Keller","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"R70-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2023.07.007","article-title":"Macular neovascularization in inherited retinal diseases: A review","volume":"69","author":"Heath Jeffery","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R71-20261103","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/archophthalmol.2011.338","article-title":"Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy","volume":"129","author":"Sohn","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R72-20261103","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.3928\/23258160-20190605-15","article-title":"Chronic choroidal neovascular membrane in choroideremia treated with intravitreal bevacizumab","volume":"50","author":"Chen","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R73-20261103","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/archopht.1996.01100140495035","article-title":"Gyrate atrophy and choroidal neovascularization","volume":"114","author":"Marano","year":"1996","journal-title":"1996\/10\/01 Arch Ophthalmol"},{"key":"R74-20261103","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.5301\/ejo.5000660","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to gyrate atrophy in a young patient: A multimodal imaging analysis","volume":"25","author":"Chatziralli","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"R75-20261103","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10792-017-0579-2","article-title":"Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab","volume":"38","author":"Inanc","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R76-20261103","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0420.2006.00872.x","article-title":"Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa","volume":"85","author":"Melo","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"R77-20261103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/02713680802710692","article-title":"Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa","volume":"34","author":"Yuzbasioglu","year":"2009","journal-title":"Curr Eye Res"},{"key":"R78-20261103","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/bjophthalmol-2019-315152","article-title":"Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa","volume":"104","author":"Strong","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R79-20261103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.preteyeres.2015.02.001","article-title":"Adult-onset foveomacular vitelliform dystrophy: A fresh perspective","volume":"47","author":"Chowers","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"R80-20261103","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/IAE.0000000000001357","article-title":"Functional and anatomical outcomes of choroidal neovascularization complicating BEST1-related retinopathy","volume":"37","author":"Khan","year":"2017","journal-title":"Retina"},{"issue":"Suppl 1","key":"R81-20261103","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.4103\/IJO.IJO_812_24","article-title":"Comprehensive review of angioid streaks","volume":"73","author":"Kandasamy","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R82-20261103","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1111\/j.1600-0420.2006.00762.x","article-title":"Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks","volume":"84","author":"Teixeira","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R83-20261103","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajo.2009.04.026","article-title":"Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks","volume":"148","author":"Sawa","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R84-20261103","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/IAE.0b013e318207d1dc","article-title":"Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum","volume":"31","author":"Finger","year":"2011","journal-title":"Retina"},{"key":"R85-20261103","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/eye.2009.83","article-title":"Intravitreal bevacizumab as an adjunct in a patient with presumed vascularised choroidal tubercular granuloma","volume":"24","author":"Babu","year":"2009","journal-title":"Eye"},{"key":"R86-20261103","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/09273948.2019.1582786","article-title":"Resolution of large choroidal tuberculoma following monotherapy with intravitreal ranibizumab","volume":"28","author":"Jain","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R87-20261103","doi-asserted-by":"crossref","first-page":"bcr2013200255","DOI":"10.1136\/bcr-2013-200255","article-title":"Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma","volume":"2013","author":"Bansal","year":"2013","journal-title":"BMJ Case Rep"},{"key":"R88-20261103","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.4103\/ijo.IJO_1261_20","article-title":"Correlation of vascular endothelial growth factor with the clinical regression of tubercular granuloma","volume":"68","author":"Agarwal","year":"2020","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3035_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:34Z","timestamp":1793732434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3035_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3035_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}